ID

36380

Descripción

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02); ODM derived from: https://clinicaltrials.gov/show/NCT01989676

Link

https://clinicaltrials.gov/show/NCT01989676

Palabras clave

Versiones (1)
  1. 8/5/19 8/5/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

8 de mayo de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Metastatic Breast Cancer NCT01989676

Inglés

Eligibility Metastatic Breast Cancer NCT01989676

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically confirmed diagnosis of breast cancer.
Descripción

Breast Carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0678222
presence of metastatic disease.
Descripción

Neoplasm Metastasis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0027627
documentation of her2 gene amplification or overexpression.
Descripción

HER2 gene amplification | HER2 Protein Overexpression

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1512127
UMLS CUI [2]
C1515560
available tumor tissue for central review of her2 status.
Descripción

Tumor tissue sample Available | Review of HER2 Status

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0475358
UMLS CUI [1,2]
C0470187
UMLS CUI [2,1]
C0699752
UMLS CUI [2,2]
C1512413
at least 1 measurable lesion as defined by recist 1.1.
Descripción

Measurable lesion Quantity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
eastern cooperative oncology group status of 0 to 2.
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
left ventricular ejection fraction within institutional range of normal, measured by either two dimensional echocardiogram or multigated acquisition scan.
Descripción

Left ventricular ejection fraction Within reference range Echocardiography 2-Dimensional | Left ventricular ejection fraction Within reference range MUGA scan

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0428772
UMLS CUI [1,2]
C0460094
UMLS CUI [1,3]
C0013516
UMLS CUI [1,4]
C1705052
UMLS CUI [2,1]
C0428772
UMLS CUI [2,2]
C0460094
UMLS CUI [2,3]
C0521317
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
relapse within 1 year of last dose of previous adjuvant (including neoadjuvant) treatment (except endocrine therapy).
Descripción

Recurrent disease | Adjuvant therapy | Neoadjuvant Therapy | Exception Hormone Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0277556
UMLS CUI [2]
C0677850
UMLS CUI [3]
C0600558
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0279025
prior systemic therapy for metastatic disease (except endocrine therapy).
Descripción

Systemic therapy Neoplasm Metastasis | Exception Hormone Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C0027627
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0279025
prior cumulative dose of doxorubicin of >400 mg/m2, epirubicin dose >800 mg/m^2, or the equivalent dose for other anthracyclines or derivatives (eg, 72 mg/m^2 of mitoxantrone). if the patient has received more than one anthracycline, then the cumulative dose must not exceed the equivalent of 400 mg/m^2 of doxorubicin.
Descripción

Doxorubicin Cumulative Dose | Epirubicin Dose | Anthracyclines Dose Equivalent | Derivative Dose Equivalent | Mitoxantrone Dose

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013089
UMLS CUI [1,2]
C2986497
UMLS CUI [2,1]
C0014582
UMLS CUI [2,2]
C0178602
UMLS CUI [3,1]
C0282564
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C0205163
UMLS CUI [4,1]
C1527240
UMLS CUI [4,2]
C0178602
UMLS CUI [4,3]
C0205163
UMLS CUI [5,1]
C0026259
UMLS CUI [5,2]
C0178602
inflammatory breast cancer.
Descripción

Inflammatory Breast Carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0278601
active uncontrolled or symptomatic central nervous system metastases.
Descripción

CNS metastases Uncontrolled | CNS metastases Symptomatic

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0686377
UMLS CUI [2,2]
C0231220
Volver a la parte superior de la página

Similar models

Eligibility Metastatic Breast Cancer NCT01989676

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Breast Carcinoma
Item
histologically confirmed diagnosis of breast cancer.
boolean
C0678222 (UMLS CUI [1])
Neoplasm Metastasis
Item
presence of metastatic disease.
boolean
C0027627 (UMLS CUI [1])
HER2 gene amplification | HER2 Protein Overexpression
Item
documentation of her2 gene amplification or overexpression.
boolean
C1512127 (UMLS CUI [1])
C1515560 (UMLS CUI [2])
Tumor tissue sample Available | Review of HER2 Status
Item
available tumor tissue for central review of her2 status.
boolean
C0475358 (UMLS CUI [1,1])
C0470187 (UMLS CUI [1,2])
C0699752 (UMLS CUI [2,1])
C1512413 (UMLS CUI [2,2])
Measurable lesion Quantity
Item
at least 1 measurable lesion as defined by recist 1.1.
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
ECOG performance status
Item
eastern cooperative oncology group status of 0 to 2.
boolean
C1520224 (UMLS CUI [1])
Left ventricular ejection fraction Within reference range Echocardiography 2-Dimensional | Left ventricular ejection fraction Within reference range MUGA scan
Item
left ventricular ejection fraction within institutional range of normal, measured by either two dimensional echocardiogram or multigated acquisition scan.
boolean
C0428772 (UMLS CUI [1,1])
C0460094 (UMLS CUI [1,2])
C0013516 (UMLS CUI [1,3])
C1705052 (UMLS CUI [1,4])
C0428772 (UMLS CUI [2,1])
C0460094 (UMLS CUI [2,2])
C0521317 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Recurrent disease | Adjuvant therapy | Neoadjuvant Therapy | Exception Hormone Therapy
Item
relapse within 1 year of last dose of previous adjuvant (including neoadjuvant) treatment (except endocrine therapy).
boolean
C0277556 (UMLS CUI [1])
C0677850 (UMLS CUI [2])
C0600558 (UMLS CUI [3])
C1705847 (UMLS CUI [4,1])
C0279025 (UMLS CUI [4,2])
Systemic therapy Neoplasm Metastasis | Exception Hormone Therapy
Item
prior systemic therapy for metastatic disease (except endocrine therapy).
boolean
C1515119 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0279025 (UMLS CUI [2,2])
Doxorubicin Cumulative Dose | Epirubicin Dose | Anthracyclines Dose Equivalent | Derivative Dose Equivalent | Mitoxantrone Dose
Item
prior cumulative dose of doxorubicin of >400 mg/m2, epirubicin dose >800 mg/m^2, or the equivalent dose for other anthracyclines or derivatives (eg, 72 mg/m^2 of mitoxantrone). if the patient has received more than one anthracycline, then the cumulative dose must not exceed the equivalent of 400 mg/m^2 of doxorubicin.
boolean
C0013089 (UMLS CUI [1,1])
C2986497 (UMLS CUI [1,2])
C0014582 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0282564 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205163 (UMLS CUI [3,3])
C1527240 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0205163 (UMLS CUI [4,3])
C0026259 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
Inflammatory Breast Carcinoma
Item
inflammatory breast cancer.
boolean
C0278601 (UMLS CUI [1])
CNS metastases Uncontrolled | CNS metastases Symptomatic
Item
active uncontrolled or symptomatic central nervous system metastases.
boolean
C0686377 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0686377 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial